文献速递高血压

含至少三种降压药的固定剂量复方制剂治疗高血压

Hypertension therapy using fixed-dose polypills that contain at least three medications.
PubMed 文献 · Heart · 2023-08-11

结果显示,标准剂量三药复方、低剂量三药及四药复方的降压效果均优于对照,且不良事件发生率相似,低剂量三药或四药复方可作为2级高血压(血压>140/90 mmHg)初治患者的一线治疗。

要点

  • 标准剂量三药复方降压幅度大于双药联合,低剂量复方优于安慰剂或单药/常规治疗。
  • 低剂量三药或四药复方在初治人群中安全有效,可考虑作为2级高血压的一线治疗。
  • 各试验不良事件发生率相似,部分研究报告用药依从性>95%。

核心结论

  • 含三种或四种降压药的固定剂量复方制剂有效,低剂量三药或四药复方可用于2级高血压初治患者的一线治疗。

主要发现

  • 标准剂量三药复方与双药联合相比,收缩压平均差异(MD)范围为-10.6至-41.4;低剂量复方与安慰剂相比,MD范围为-9.8至-20.6;低剂量复方与单药或常规治疗相比,MD范围为-9.0至-29.3。
  • 所有试验报告的不良事件发生率相似,10项研究报告了用药依从性,其中6项报告依从性>95%。

关键数值与推荐

  • 标准剂量三药复方对比双药联合的收缩压MD为-10.6至-41.4,双药联合为2.1至-34.5。
  • 低剂量复方对比安慰剂的收缩压MD为-9.8至-20.6,安慰剂为-0.9至-5.2。
  • 低剂量复方对比单药或常规治疗的收缩压MD为-9.0至-29.3,单药或常规治疗为-2.0至-20.6。
  • 低剂量三药或四药复方可用于2级高血压(血压>140/90 mmHg)初治患者的一线治疗。

临床怎么用

  • 对于2级高血压(血压>140/90 mmHg)初治患者,可考虑起始使用低剂量三药或四药固定剂量复方制剂。
  • 固定剂量复方制剂可能有助于克服治疗惰性,缩小治疗差距。

局限性

  • 未报告各试验的具体设计细节、随访时长及人群基线特征。
  • 未报告复方制剂的具体药物组成及剂量信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fixed-dose combination (FDC) therapy may provide a solution to treatment gaps by overcoming reasons for therapeutic inertia. To synthesise and report on available evidence on standard or low-dose combination medicines that combine at least three antihypertensive medicines. A literature search was conducted via Scopus, Embase, PubMed and the Cochrane clinical trials database. Studies were eligible for inclusion if they were randomised clinical trials that included adults (>18 years) and examined the impact of at least three antihypertensive medications on blood pressure (BP). A total of 18 trials (n=14 307) were identified that examined combinations of three or four antihypertensive medicines. Ten trials investigated the effect of a standard dose triple combination polypill, four the effect of a low-dose triple and four the effect of a low-dose quadruple combination polypill. The mean difference (MD) in systolic BP ranged from -10.6 to -41.4 for the standard dose triple combination polypill in comparison with 2.1 to -34.5 for dual combination; -9.8 to -20.6 for a low-dose combination polypill in comparison with a MD of -0.9 to -5.2 for placebo; -9.0 to -29.3 for a low-dose combination polypill compared with -2.0 to -20.6 for monotherapy or usual care. All trials reported similar rates of adverse events. Ten studies reported medication adherence, six reported >95% adherence. Triple and quadruple combination antihypertensive medications are effective. Studies of low-dose triple and quadruple combinations involving treatment naïve populations suggest initiating such combinations are safe and effective as first-line therapy for stage 2 hypertension (BP >140/90 mm Hg).

来源:Heart,查看原文。版权归原作者所有。

引用

  1. O'Hagan ET, McIntyre D, Nguyen T, et al. Hypertension therapy using fixed-dose polypills that contain at least three medications. Heart. 2023. PMID: 36810213. doi:10.1136/heartjnl-2022-321496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。